Obermeyer Wood Investment Counsel Lllp Sells 479 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Obermeyer Wood Investment Counsel Lllp cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 30.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,108 shares of the medical research company’s stock after selling 479 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Thermo Fisher Scientific were worth $588,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Xponance Inc. boosted its stake in Thermo Fisher Scientific by 4.8% in the fourth quarter. Xponance Inc. now owns 76,761 shares of the medical research company’s stock worth $40,744,000 after purchasing an additional 3,487 shares in the last quarter. AIA Group Ltd boosted its position in Thermo Fisher Scientific by 32.8% during the fourth quarter. AIA Group Ltd now owns 14,448 shares of the medical research company’s stock valued at $7,669,000 after purchasing an additional 3,568 shares during the last quarter. Integral Investment Advisors Inc. boosted its position in Thermo Fisher Scientific by 3.4% during the fourth quarter. Integral Investment Advisors Inc. now owns 1,388 shares of the medical research company’s stock valued at $737,000 after purchasing an additional 46 shares during the last quarter. Ninety One SA PTY Ltd boosted its position in Thermo Fisher Scientific by 5.9% during the fourth quarter. Ninety One SA PTY Ltd now owns 21,183 shares of the medical research company’s stock valued at $11,244,000 after purchasing an additional 1,179 shares during the last quarter. Finally, Peterson Wealth Services lifted its position in shares of Thermo Fisher Scientific by 5.6% in the fourth quarter. Peterson Wealth Services now owns 6,616 shares of the medical research company’s stock valued at $3,512,000 after buying an additional 353 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TMO shares. The Goldman Sachs Group raised their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. HSBC raised their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research report on Wednesday. Raymond James raised their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Stock Down 1.0 %

TMO traded down $5.47 on Thursday, hitting $541.78. The company had a trading volume of 2,075,782 shares, compared to its average volume of 1,547,352. The stock has a fifty day simple moving average of $571.57 and a 200-day simple moving average of $527.01. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The firm has a market capitalization of $206.80 billion, a P/E ratio of 34.94, a P/E/G ratio of 2.33 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the business earned $5.40 earnings per share. The business’s revenue was down 4.9% on a year-over-year basis. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.